Richie Cunningham, TYME Technologies CEO
Microcap cancer player goes belly up after pancreatic tumor hopeful flops key study
TYME Technologies’ SM-88 has been pulled from a Phase II/III study after a clinical trial sponsor clued the biotech in on an expected failure for …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
